The latest data point for LLY's Revenue Surprise % in Q1'26 stands at 11.11%, indicating a positive surprise relative to analyst expectations and marking a notable uptick from the previous quarter's 7.51%. Meanwhile, Revenue Growth (YoY) reached 55.55% in the same period, reflecting robust year-over-year expansion driven by strong performance in key pharmaceutical segments. Over the timeframe from Q2'23 to Q1'26, Revenue Surprise % exhibited volatility, starting strong at 9.62% in Q2'23 before dipping to a low of -5.44% in Q3'24 and gradually recovering to positive territory, with an overall upward trend in recent quarters suggesting improving alignment with or exceeding forecasts. In contrast, Revenue Growth (YoY) showed consistent strength, fluctuating between 20.43% and 55.87% but trending higher post-Q3'24, peaking at 55.55% in Q1'26, which highlights sustained momentum in revenue expansion despite occasional surprises below expectations.